May 17, 2020

The True Cost Of Healthcare

healthcare
financial
cost of healthcare
National Health S
Admin
4 min
An In Depth Analysis Of Global National Health Services
Follow @HealthCareG Written by ShuktiSarma For any state, it is a must to provide public welfare utilities, and healthcare is the most important and u...

 

Written by Shukti Sarma

For any state, it is a must to provide public welfare utilities, and healthcare is the most important and universal service that comes under the agenda. All welfare states devote tremendous amount of time, resources and energy in setting up national health services, but what is the significance of having such a welfare system in place?

Probably the most well known debate on providing national healthcare to citizens in recent times has centered on Obamacare, or the Patient Protection and Affordable Care Act (PPACA). This federal law represents the most significant regulatory overhaul of the US healthcare system since the passage of Medicare and Medicaid in 1965. With equal measures of scorn and praise coming in the US President’s way, it is time to see what exactly it costs the country to take care of its citizens.

Read This Article In Our Digital Reader

HCGCoverMarchSml.jpg

Obamacare & More: Health Is Wealth

While Obamacare is definitely the most talked about health care system in recent times, in no way is the US unique. Most countries have a social healthcare system in place. The advantages are obvious: healthcare is one of the basic human needs, and it is only fair that the state which draws its powers and wealth from the people gives them back. It is indeed, a citizen’s right to have a healthy life.

A health system is particularly indispensable where there is a big gap between the different strata of society. Healthcare becomes a luxury for the disadvantaged, who often cannot afford healthcare, and may not even have access to healthcare. When the state steps in, no citizen can be denied their rights.

Another important area of concern is medical insurance. It is a must for every individual, but most cannot afford it. A state system which provides medical insurance to its citizens can not only be expected to be fair and reasonable, but is less likely to cheat and harass patients, which is widespread in the private healthcare insurance sector.

When healthcare is state regulated or provided by the state, a lot of unfair practices are curbed. Many private hospitals are infamous for charging unreasonable amount for services, and there is little room for protest. In a state-regulated healthcare system, prices and services are fair across the spectrum, and such important information is available to the patients who otherwise, may be cheated. Also, while private healthcare providers may refuse to treat patients who cannot afford the treatment, a state is duty bound to provide the service.

Most importantly, a government is capable to summoning more resources than any private entity, and hence, the reach of a public healthcare system is vast. Constructing a hospital in a remote, poorly populated area may not be possible for a private healthcare provider- neither can they be held accountable for it. But for the government, not only is this possible, but also a matter of duty towards its citizens and must be done.

Financial Health?

While the advantages of a national health service clearly justify its existence, there are some concerns to be addressed as well. A national healthcare system is also a huge burden on the state. A national health system has universal reach, and it is only fair that the state offers pro-bono treatment to its disadvantaged citizens. But in order to subsidise that cost, it also requires a premium level income, which can come only from the rich patients. But state healthcare systems rarely focus on the premium segment, and hence, it is a field where the government has all expenditure and little income.

The question of finance also comes up when talking of medical insurance, which by default is expensive. A public welfare system being highly subsidized, providing insurance to citizens is a huge financial burden.

And lastly, there is the question of service and corruption. This problem is especially acute in developing countries. There is a perception that government run hospitals do not provide quality service- and this observation is not always incorrect. Corruption makes a mockery of the noble intentions and instead, subjects citizens to blackmail. Sadly, in many such cases, corrupt government employees go unpunished.

Duty First

But everything considered, healthcare is a necessity, and one of the primary responsibilities of a state. A national system may be a financial burden, and it may be subject to human vices like every other institution, but that cannot be reasons enough to shirk the responsibility. It is every citizen’s right to get access to healthcare. A national healthcare service may be costly, but that does not even come close to the value of life.

Share article

Jun 10, 2021

The future of pharma: personalised healthcare

#pharma
#personalisedmedicine
#genomics
#diagnostics
6 min
Chris Easton, Global Commercial Lead at Takeda, tells us how the pharmaceutical sector can help deliver more personalised care

Ever since the very first healthcare systems were created, the earliest documented being in ancient Egypt, medical professionals have had a reactionary approach   to finding cures for ailments. That is to say that a solution is sought after someone has become sick, using whatever methods were thought to work at the time. Thousands of years later, with advances in genomics and molecular modelling, emphasis is starting to shift towards preventative, personalised healthcare rather than "sick care". 

This move is led by data analytics as well as genetic sequencing to inform decision-making, which can ultimately lead to more individualised care. "Identifying the right data will support personalised health outcomes", explains Chris Easton, who is Takeda’s Senior Director and Global Commercial Lead, specialising in personalised health and innovation and applying this to rare blood disorders. "It's about how we can empower patients, interpret data and then apply it."

"The historic pharma model, in a very simplified form, is: a patient has symptoms, gets diagnosed, and gets given drugs for symptoms", Easton says. "Now, with holistic patient care in mind, it's much more about the additional components to care that would make a difference. Yes, drug therapy is one of them, but likewise, it's okay to talk about mental health, as the impact of chronic diseases means often there is a mental health challenge. So what can we do to build a mental health and physical health support package, both of which have data associated with them, that we can use together?"

By way of example, Easton cites the approach taken by elite athletes and astronauts. "Their model is to keep as healthy as possible. If someone on a space mission gets a cold, they're off the mission - it's not affordable to send someone to space that might have a health issue. If you look at footballers and runners, their coaches maintain them at the highest level, and they're using technology and wearables to help monitor their health so that they can make adjustments to stay at peak level for as long as possible." 

The aim is to provide a complete, holistic package of care, which Easton acknowledges will pose some challenges to the pharmaceutical sector. "Our model is not necessarily that of a total care package. It's drug therapy or device and technology support therapy. So some things will need to evolve, and that's part of what my role is about." 

One way of effecting this change is by collaborating with other organisations, not necessarily limited to healthcare and life sciences. "I'm a big advocate of partnerships and joint ventures. For the pharma sector, these are traditionally through universities and research houses, but I think we need to be willing to look outside the box and look for scalable and transferable technology that is used in everyday life." 

"An example is the smartphone you probably have sitting on your desk or the smartwatch you're wearing.  These are gathering data all the time. There are probably hundreds of data points that we could use, just from our everyday technology", Easton adds. 

While apps like Apple Health, Google Health, and devices like Fitbit collect data, they could be linked to WhatsApp, WeChat or Telegraph to connect to members of a user's care team if a health issue arises. "It's using technology that is already embedded in our lives, that would enable us to share information and photographs. For example, if your knee is swelling and you want to ask a doctor for their opinion, you can send an image, then share the log from your treatment, and it becomes a way of integrating and sharing information." 

Shifting towards preventative medicine is one of Takeda's strategic goals for the next few years. An example of how this could work is how people affected by Von Willebrand disease could be supported. This lifelong bleeding disorder prevents blood from clotting and particularly affects girls and women, causing menstrual bleeding to be excessively long and heavy, which has a big impact on their quality of life. 

"It's a hereditary disorder, so many women in a family can be affected, but it's hard to diagnose", Easton explains. However, using existing technology that tracks the menstrual cycle via a smartphone perhaps an alert can be issued to let the user know when it's time to start taking replacement therapy for Von Willebrand. 

"This means that by the time a period begins, Von Willebrand levels are normalised, and menstrual flow goes down to normal levels. That's actually a massive outcome for someone who has been living with two-week-long periods that bleed through clothing every month. Suddenly for just four or five days, they can use regular tampons and pads. That's a huge improvement to life." 

The field of rare blood disorders typically hasn't seen the same amount of attention focused on it - at least in terms of tech innovation - as other chronic illnesses like diabetes. "Rare blood disorders are difficult to show returns on because you've got small patient numbers and often high costs. But if we think about the total patient journey, we could use technology to triage vast numbers of patients and data into more specific diagnosis boxes, so that what is then presented to physicians are smaller groups, of the more likely issues."

Data analysis could, for instance, show that the combination of headaches, nausea and lethargy equates to a specific type of bleeding disorder.  "You can start to put these things in categories", Easton says. "And then you're able to do differential diagnosis. But ultimately, what you're trying to do is get a faster, more accurate diagnosis, leading to a specific therapy." 

This would be more efficient than administering plasma-based treatments, for example. "A lot of bleeding disorders are caused by a deficiency of something", Easton explains. "There is a lot of combination therapy in blood disorders when you give people plasma-based products because plasma is like the golden chalice of medicine. It has a bit of everything you need. In some cases, when you don't know what the disorder is, this can help patients, but it's not the most precise way of doing it."

"That's one of the ways having very clear diagnostic support linked to advanced direct therapy can help, only treating what you need to. From a payer's perspective, it's very targeted, and there's no wasting money and resources on patients being hospitalised for things that are not necessary."

"If you go back 15-20 years, market access to the pharmaceutical industry was the emerging trend", Easton adds. "We saw all these diagrams of physician decision-making coming down and payer decision-making going up. Now we have another divergence of change, which is the application of technology to support personalised care.  This is one of the transformative pieces of pharma right now, and there are a lot of good companies, big and small, being very intelligent about how they're approaching it and investing in those spaces. There's definitely a community building." 

Share article